CXCR4 and myeloid sarcoma: The CXCR4 antagonist plerixafor that induces rapid mobilization (51) might be worth evaluating for its potential morbidity in the MS setting and for the capacity of MPP mobilized with this alternative agent to expand Treg to the same extent as those obtained after G-CSF mobilization.